Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-02-13 4:16 pm Purchase | 13D | PEPGEN INC PEPG | RA CAPITAL MANAGEMENT L.P. | 10,695,135 34.1% | 2,563,183 (+31.52%) | View |
2024-02-12 4:49 pm Purchase | 13D | MINERALYS THERAPEUTICS INC MLYS | RA CAPITAL MANAGEMENT L.P. | 4,949,307 9.99% | 1,768,387 (+55.59%) | View |
2024-02-12 4:18 pm Purchase | 13G | CORBUS PHARMACEUTICALS HOLDING CRBP | RA CAPITAL MANAGEMENT L.P. | 430,182 4.1% | 430,182 (New Position) | View |
2024-02-12 4:17 pm Purchase | 13G | ASTRIA THERAPEUTICS INC ATXS | RA CAPITAL MANAGEMENT L.P. | 4,413,150 8.1% | 4,413,150 (New Position) | View |
2024-02-06 4:40 pm Purchase | 13D | TYRA BIOSCIENCES INC TYRA | RA CAPITAL MANAGEMENT L.P. | 10,475,489 19.99% | 3,239,035 (+44.76%) | View |
2024-02-05 4:30 pm Purchase | 13G | ADICET BIO INC ACET | RA CAPITAL MANAGEMENT L.P. | 7,696,949 9.99% | 7,696,949 (New Position) | View |
2024-02-01 6:22 pm Purchase | 13G | DIANTHUS THERAPEUTICS INC DNTH | RA CAPITAL MANAGEMENT L.P. | 2,995,023 9.99% | 2,995,023 (New Position) | View |
2024-01-29 4:30 pm Purchase | 13G | EDGEWISE THERAPEUTICS INC EWTX | RA CAPITAL MANAGEMENT L.P. | 8,909,091 9.6% | 8,909,091 (New Position) | View |
2024-01-19 4:30 pm Purchase | 13G | VAXART INC VXRT | RA CAPITAL MANAGEMENT L.P. | 15,384,615 9.1% | 15,384,615 (New Position) | View |
2024-01-12 5:00 pm Purchase | 13G | LONGBOARD PHARMACEUTICALS INC LBPH | RA CAPITAL MANAGEMENT L.P. | 3,073,119 8.7% | 3,073,119 (New Position) | View |
2024-01-11 5:24 pm Purchase | 13D | SOLID BIOSCIENCES INC SLDB | RA CAPITAL MANAGEMENT L.P. | 4,348,828 11.7% | 917,210 (+26.73%) | View |
2023-12-29 4:30 pm Purchase | 13G | UROGEN PHARMA LTD URGN | RA CAPITAL MANAGEMENT L.P. | 3,083,550 9.99% | 3,083,550 (New Position) | View |
2023-12-26 4:30 pm Purchase | 13G | C4 THERAPEUTICS INC CCCC | RA CAPITAL MANAGEMENT L.P. | 4,878,000 9.9% | 4,878,000 (New Position) | View |
2023-12-20 4:30 pm Sale | 13D | CONNECT BIOPHARMA HLDGS LTD CNTB | RA CAPITAL MANAGEMENT L.P. | 3,062,871 5.6% | -2,061,438 (-40.23%) | View |
2023-12-14 4:30 pm Sale | 13D | CONNECT BIOPHARMA HLDGS LTD CNTB | RA CAPITAL MANAGEMENT L.P. | 5,124,309 9.3% | -830,702 (-13.95%) | View |
2023-12-13 4:30 pm Purchase | 13D | 89BIO INC ETNB | RA CAPITAL MANAGEMENT L.P. | 12,875,855 13.6% | 1,041 (+0.01%) | View |
2023-12-04 5:20 pm Sale | 13D | CONNECT BIOPHARMA HLDGS LTD CNTB | RA CAPITAL MANAGEMENT L.P. | 5,955,011 10.8% | -1,035,992 (-14.82%) | View |
2023-11-27 4:30 pm Purchase | 13G | THIRD HARMONIC BIO INC THRD | RA CAPITAL MANAGEMENT L.P. | 2,033,056 5% | 1,498,369 (+280.23%) | View |
2023-11-17 4:30 pm Purchase | 13D | ELIEM THERAPEUTICS INC ELYM | RA CAPITAL MANAGEMENT L.P. | 13,176,403 47.7% | 13,332 (+0.10%) | View |
2023-11-14 5:00 pm Sale | 13G | DESIGN THERAPEUTICS INC DSGN | RA CAPITAL MANAGEMENT L.P. | 0 0% | -2,971,231 (Position Closed) | View |